News
Numerous advocacy organizations are sounding the alarm over a recent HHS notice that restricts access to federal benefits for ...
Healthcare providers are making cybersecurity progress, but serious vulnerabilities remain — especially when it comes to AI ...
Opinion
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly Lawsuit
This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
A bill introduced by Rep. Earl L. "Buddy" Carter would ban PBMs’ use of spread pricing in Medicaid, among other reforms.
Roivant Sciences built a business out of scouting for overlooked drug candidates that stalled in the labs of pharmaceutical companies or universities and bringing them in-house to develop under ...
Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has ...
Most patients are open to the use of AI in healthcare — as long as it enhances, rather than replaces, human interaction, according to new research. It also showed that patients want transparency ...
Hospital M&A activity slowed quite a bit in the first half of 2025, with deal volume and transacted revenue falling sharply amid economic uncertainty and sweeping policy changes. While traditional ...
Little is known or reported about the procedures used to sample blood from midline catheters or outcomes from using the MC for this purpose.
A new survey from Mercer found that 51% of large employers said they are likely or very likely to make health benefit changes that would shift more costs to employees.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results